References
- Masters, P. S. The Molecular Biology of Coronavirus. Adv. Virus. Res. 2006, 66, 193–292.
- Wu, F.; Zhao, S.; Yu, B.; Chen, Y. M.; Wang, W.; Song, Z. G.; Hu, Y.; Tao, Z. W.; Tian, J. H.; Pei, Y. Y.; et al. A New Coronavirus Associated with Human Respiratory Disease in China. Nature 2020, 579, 265–269.
- Zhou, P.; Yang, X. L.; Wang, X. G.; Hu, B.; Zhang, L.; Zhang, W.; Si, H. R.; Zhu, Y.; Li, B.; Huang, C. L.; et al. A Pneumonia Outbreak Associated with a New Coronavirus of Probable Bat Origin. Nature 2020, 579, 270–273.
- Yuan, L.; Tang, Q.; Chen, T.; Xia, N. Animal Models for Emerging Coronavirus: Progress and New Insights. EMI 2020, 9, 949–961.
- Tai, W.; He, L.; Zhang, X.; Pu, J.; Voronin, D.; Jiang, S.; Zhou, Y.; Du, L. Characterization of the Receptor-Binding Domain (RBD) of 2019 Novel Coronavirus: Implication for Development of RBD Protein as a Viral Attachment Inhibitor and Vaccine. Cell. Mol. Immunol. 2020, 17, 613–620.
- Hu, T.; Liu, Y.; Zhao, M.; Zhuang, Q.; Xu, L.; He, Q. A Comparison of COVID-19, SARS and MERS. PeerJ 2020, 8, e9725.
- Amanat, F.; Krammer, F. SARS-CoV-2 Vaccines: Status Report. Immunity 2020, 52, 583–589.
- Wang, Y.; Zhou, F.; Zhang, D.; Zhao, J.; Du, R.; Hu, Y.; Chen, Z.; Gao, L.; Jin, Y.; Luo, G.; et al. Evaluation of the Efficacy and Safety of Intravenous Remdesivir in Adult Patients with Severe COV COVID-19: Study Protocol for a Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicentre Trial. Trials 2020, 21, 422.
- Gilead Sciences, Inc. U.S. Food and Drug Administration Approves Gilead’s Antiviral Veklury (Remdesivir) for Treatment of COVID-19. 22 October 2020. https://www.gilead.com/ness-and-press/press-room/press-releases/2020/10/us-food-and-drug-administration-approves-gileads-antiviral-veklury-remdesivir-for-treatment-of-covid19 (accessed Oct 23, 2020).
- World Health Organization. Therapeutics and COVID-19: Living Guideline, 20 November 2020. World Health Organization (WHO) (Report). hdl:10665/336729. https://hdl.handle.net/10665%2F336729. WHO/2019-nCov/remdesivir,2020.1.
- Beigel, J. H.; Tomashek, K. M.; Dodd, L. E.; Mehta, A. K.; Zingman, B. S.; Kalil, A. C.; Hohmann, E.; Chu, H. Y.; Luetkemeyer, A.; Kline, D.; et al. Remdesivir for the Treatment of Covid-19-Final Report. N. Engl. J. Med. 2020, 383, 1813–1826.
- Goldman, J. D.; Lye, D. C. B.; Hui, D. S.; Marks, K. M.; Bruno, R.; Montejano, R.; Spinner, C. D.; Galli, M.; Ahn, M. Y.; Nahass, R. G.; et al. Remdesivir for 5 or 10 Days in Patients with Severe Covid-19. N. Engl. J. Med. 2020, 383, 1827–1837.
- Kalil, A. C.; Mehta, A. K.; Tomashek, K. M.; Wolfe, C. R.; Ghazaryan, V.; Marconi, V. C.; Ruiz-Palacios, G. M.; Hsieh, L.; Kline, S.; Tapson, V.; et al. Baricitinib Plus Remdesivir for Hospitalized Adults with Covid-19. N. Engl. J. Med. 2021, 384, 795–807.
- Kumata, R.; Ito, J.; Takahashi, K.; Suzuki, T.; Sato, K. A Tissue Level Atlas of the Healthy Human Virome. BMC Biol. 2020, 18, 55.
- Osborne, V.; Davies, M.; Lane, S.; Evans, A.; Denyer, J.; Dhanda, S.; Roy, D.; Shakir, S. Lopinavir-Ritonavir in the Treatment of COVID-19: A Dynamic Systematic Benefit-Risk Assessment. Drug Saf. 2020, 43, 809–821.
- Dalerba, P.; Levin, B.; Thompson, J. L. A Trial of Lopinavir-Ritonavir in COVID-19. N. Engl. J. Med. 2020, 382, e68.
- Nojomi, M.; Yassin, Z.; Keyvani, H.; Makiani, M. J.; Roham, M.; Laali, A.; Dehghan, N.; Navaei, M.; Ranjbar, M. Effect of Arbidol (Umifenovir) on COVID-19: A Randomized Controlled Trial. BMC Infect. Dis. 2020, 20, 954.
- Shi, R.; Shan, C.; Duan, X.; Chen, Z.; Liu, P.; Song, J.; Song, T.; Bi, X.; Han, C.; Gao, G.; et al. A Human Neutralizing Antibody Targets the Receptor-Binding Site of SARS-CoV-2. Nature 2020, 584, 120–124.
- Chen, P.; Nirula, A.; Heller, B.; Gottlieb, R. L.; Boscia, J.; Morris, J.; Huhn, G.; Cardona, J.; Mocherla, B.; Stosor, V.; et al. SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19. N. Engl. J. Med. 2021, 384, 229–237.
- Kim, C.; Ryu, D. K.; Lee, J.; Kim, Y. I. I.; Seo, J. M.; Kim, Y. G.; Jeong, J. H.; Kim, M.; Kim, J. L.; Kim, P.; et al. A Therapeutic Neutralizing Antibody Targeting Receptor Binding Domain of SARS-CoV-2 Spike Protein. Nat. Commun. 2021, 12, 288. DOI: 10.1038/s41467-020-20602-5.
- Weisblum, Y.; Schmidt, F.; Zhang, F.; DaSilva, J.; Poston, D.; Lorenzi, J. C. C.; Muecksch, F.; Rutkowska, M.; Hoffmann, H. H.; Michailidis, E.; et al. Escape from Neutralizing Antibodies by SARS-CoV-2 Spike Protein Variants. eLife 2020, 9, e61312.
- Cheng, M. H.; Krieger, J. M.; Kaynak, B.; Arditi, M.; Bahar, I. Impact of South African 501.V2 Variant on SARS-CoV-2 Spike Infectivity and Neutralization: A Structure-Based Computational Assessment. Bioinformatics 2021. DOI: 10.1101/2021.01.10.426143.
- Chen, R. E.; Zhang, X.; Case, J. B.; Winkler, E. S.; Liu, Y.; VanBlargan, L. A.; Liu, J.; Errico, J. M.; Xie, X.; Suryadevara, N.; et al. Resistance of SARS-CoV-2 Variants to Neutralization by Monoclonal and Serum- Derived Polyclonal Antibodies. Nat. Med. 2021, 27, 717–726. DOI: 10.1038/s41591-021-01294-w.
- Beigel, J. H.; Voell, J.; Kumar, P.; Raviprakash, K.; Wu, H.; Jiao, J. A.; Sullivan, E.; Luke, T.; Davey, R. T., Jr. Safety and Tolerability of a Novel, Polyclonal Human anti-MERS Coronavirus Antibody Produced from Transchromosomic Cattle: A Phase 1 Randomised, Double-Blind, Single-Dose-Escalation Study. Lancet Infect. Dis. 2018, 18, 410–418.
- Hashem, A. M.; Alghmdi, B. S.; Algaissi, A. A.; Alshehri, F. S.; Bukhari, A.; Alfaleh, M.; Memish, Z. A. Therapeutic Use of Chloroquine and Hydroxychloroquine in COVID-19 and Other Viral Infections: A Narrative Review. Travel Med. Infect. Dis. 2020, 35, 101735.
- Sun, J. K.; Chen, Y. T.; Fan, X. D.; Wang, X. Y.; Han, Q. Y.; Liu, Z. W. Advances in the Use of Choloquine and Hydroxychloroquine for the Treatment of COVID-19. Postgrad. Med. 2020, 132, 604–613. DOI: 10.1080/00325481.2020.1778982.
- Falcao, F.; Viegas, E.; Carmo, I.; Soares, J., Falcao, M.; Solano, M.; Cavaco, P.; Mendes, D.; Rijo, J.; Povoa, P.; Martins, A.; et al. A Prospective Observational Study to Evaluate Adverse Drug Reactions in Patients with COVID-19 Treated with Remdesivir or Hydroxychloroquine: A Preliminary Report. Eur. J. Hosp. Pharm. 2021, 1–6. DOI: 10.1136/ejhpharm-2020-002613.
- Wise, J. Covid-19: New Coronavirus Variant Is Identified in UK. BMJ 2020, 371, m4857. DOI: 10.1136/bmj.m4857.
- Goo, J.; Jeong, Y.; Park, Y. S.; Yang, E.; Jung, D. I.; Rho, S.; Park, U.; Sung, H.; Park, P. G.; Choi, J.; et al. Characterization of Novel Monoclonal Antibodies against MERS-Coronavirus Spike Protein. Virus. Res. 2020, 278, 197863.
- Korber, B.; Fischer, W. M.; Gnanakararan, S.; Yoon, H.; Theiler, J.; Abfalterer, W.; Hengartner, N.; Giorgi, E. E.; Bhattacharya, T.; Foley, B.; et al. Tracking Changes in SARS-CoV-2 Spike: Evidence That D614G Increases Infectivity of the COVID 19 Virus. Cell 2020, 182, 812–827.e19.
- Volz, E.; Hill, V.; McCrone, J. T.; Price, A.; Jorgensen, D.; O’Toole, A.; Southgate, J.; Johnson, R.; Jackson, B.; Nascimento, F. F.; et al. Evaluating the Effects of SARS-CoV-SARS-CoV-2 Spike Mutation D614G on Transmissibility and Pathogenicity. Cell 2021, 184, 64–75.
- Hodcroft, E.; Zuber, M.; Nadeau, S.; Crawford, K. H. D.; Bloom, J. D.; Veesler, D.; Vaughan, T. G.; Comas, I.; Candelas, F. G.; Stadler, T.; et al. Emergence and Spread of a SARS-CoV-2 Variant through Europe in the Summer of 2020. medRxiv Preprint 2020. DOI: 10.1101/2020.10.25.20219063. this version posted November 27, The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
- Chand, M.; Hopkins, S.; Dabrera, G.; Achison, C.; Barclay, W.; Ferguson, N.; Volz, E.; Loman, N.; Rambaut, A.; Barrett, J. Investigation of Novel SARS-COV-2 Variant: Variant of Concern 202012/01. 21 December 2020. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/947048/Technical_Briefing_VOC_SH_NJL2_SH2.pdf (PDF) (Report). Public Health England (accessed Dec 22, 2020).
- PHE Investigating a Novel Strain of COVID-19. 14 December 2020. Public Health England. http://www.gov.uk/government/news/phe-investigating-a-novel-stain-of-covid-19.
- Andrew, R.; Nick, L.; Oliver, P.; Wendy, B.; Jeff, B.; Alesandro, C.; Tom, C.; Tom, P.; David, L. R.; Erik, V. 2020. Preliminary Genomic Characterization of an Emergent SARS-CoV-2 Lineage in the UK Defined by a Novel Set of Spike Mutations. https://virological.org/t/preliminary-genomic-characterization-of-an-emergent-sars-cov-2-lineage-in-the-uk-defined-by-a-novel-set-of spike-mutations/563 (Report). Written on behalf of COVID-19 Genomics Consortium UK (accessed Dec 20, 2020).
- Kai, K. Mutant Coronavirus in the United Kingdom Sets off Alarms but Its Importance Remains Unclear. Science Mag, 20 December 2020. https://www.sciencemag.org/news/2020/12/mutant-coronavirus-united-kingdom-sets-alarms-its-importance-remains-unclear (accessed Dec 21, 2020).
- Peacock, S. Here’s What We Know about the New Variant of Coronavirus. The Guardian, 22 December 2020. https://www.theguardian.com/commentisfree/2020/dec/22/new-variant-coronavirus-genomic-sars-cov-2-pandemic.
- Davies, N. G.; Jarvis, C. I.; Edmunds, W. J.; Jewell, N. P.; Diaz-Ordaz, K.; Keogh, R. H.; CMMID COVID-19 Working Group. Increased Mortality in Community-Tested Cases of SARS-CoV-2 Lineage B.1.1.7. Nature 2021. (Accelerated Article Preview Published online 15 March) DOI: 10.1038/s41586-021-03426-1.
- Challen, R.; Brooks-Pollock, E.; Read, J. M.; Dyson, L.; Tsaneva-Atanasova, K.; Danon, L. Risk of Mortality in Patients Infected with SARS-CoV-2 Variant of Concern 202012/1: Matched Cohort Study. BMJ 2021, 372, n579. DOI: 10.1136/bmj.n579.
- Expert Reaction New Restrictions and the New SARS-CoV-2 Variant. Science Media Centre. https://www.sciencemediacentre.org/expert-reaction-to-pms-and-cmos-statements-about-new-restrictions-and-the-new-sars-cov-2variant/ (accessed Dec 21, 2020).
- New Coronavirus Variant: What Do We Know? BBC. https://www.bbc.co.uk/news/health-55388846 (accessed Dec 22, 2020).
- Statement of the WHO Working Group on COVID-19 Animal Models (WHO-COM) about the UK and South African SAR-CoV-2 New Variants. World Health Organization, 22 December 2020. https://www.who.int/docs/default-source/blue-print/who-com-statement_new-variant_rev1.pdf?sfvrsn=b87cOad8_3&download=true (accessed Dec 23, 2020).
- South Africa Announces a New Coronavirus Variant. The New York Times. 18 December 2020. https://www.nytimes.com/2020/12/19/world/south-africa-announces-a-new-coronavirus-variant.html (accessed December 20, 2020). “N501Y …has been found in other countries, including the United Kingdom”.
- Lesley, W.; Max, B. South Africa Coronavirus: Second Wave Fueled by New Starin, Teen “Rage Festival”. The Washington Post. 18 December 2020. https://www.washintonpost.com/world/africa/south-africa-coronavirus-second-wave/2020/12/18/d4a51aec-3ff7-11eb-b58b-1623f6267960_story.html. Archived (https://archive.today/rOyDx) from the original on 27 December 2020 (accessed December 20, 2020).
- Zweloni, M. Update on Covid-19. 18 December 2020. https://Sacoronavirus.co.za/2020/12/18/update-on-covid-19-18th-december-2020/ (Press release). South Africa. COVID-19 South African Online Portal (accessed December 23, 2020). “Our clinicians have also warned us that things have changed and that younger, previously healthy people are now becoming very sick”.
- Derek, L. The New Mutations. 22 December 2020. https://blogs.sciencemag.org/pipeline/archives/2020/12/22/the-new-mutations. In The Pipeline. American Association for the Advancement of Science (accessed Dec 23, 2020). “I should note here that there’s another strain in South Africa that is bringing on similar concerns. This one has eight mutations in the spike protein, with three of them (K417N, E484K and N501Y) that may have some functional role”.
- Expert Reaction to South African Variant of SARS-CoV-2. https://www.sciencemediacentre.org/expert-reaction-to-south-african-variant-of-sars-cov-2-as-mentioned-by-matt-hancock=at-the-downing-street-press-briefing/ (accessed Dec 26, 2020).
- Expert Reaction to South African Variant of SARS-CoV-2. Science Media Centre. 23 December 2020. https://www.sciencemediacentre.org/expert-reaction-to-south-african-variant-of-sars-cov-2-as-mentioned-by-matt-hancock=at-the-downing-street-press-briefing/ (accessed Dec 24, 2020). “The South African variant “501.V2” is characterized by N501Y, E484K and K417N mutations in the S protein-so it shares the N501Y mutation with the UK variant, but the other two mutations are not found in the UK variant. Similarly, the South African variant does not contain the 69-70del mutation that is found in the UK variant”.
- Salim, A. K. The 2nd COVID-19 Wave in South Africa: Transmissibility & a 501.V2 variant. 19 December 2020. https://www.scribd.com/document/488618010/Full-Pressentation-by-SSAK-18-Dec (accessed Dec 24, 2020). Scribd.CAPRISA. p. 11.
- South African Covid Variant Discovered in Switzerland. BusinessInsider. https://www.businessinsider.co.za/south-african-covid-variant-discovered-in-switzerland-2020-12 (accessed Dec 29, 2020).
- Update: New UK, South African Variant Covid Strains Detected in Finland. Yle News. https://www.yle.fi/uutiset/osasto/news/update_new_uk_south_african_variant_covid_strains_detected_in_finland/11716211 (accessed Dec 29, 2020).
- South African Coronavirus Variant Found in Japan. News24. https://www.new24.com/news24/world/news/south-african-coronavirus-variant-found-in-japan-20201229 (accessed Dec 29, 2020).
- First Case of ‘More Contagious’ Coronavirus Strain Detected in Australia. 9 News. 29 December 2020. https://www.9news.com.au/national/first-case-of-south-african-coronavirus-strain-detected-in-australia-in-queensland-returned-traveller/26cb85c6-1fcO-45ad-968d-b5a689dda620.
- Second COVID-19 Wave Confirmed in Zambia. Xinhua News Agency. 30 December 2020. https://www.xinhuanet.com/english/2020-12/30/c_139630370.htm.
- P.1 Report. cov-lineages.org. https://cov-lineages.org/global_report_P.1.html (accessed Feb 8, 2021).
- Zhang, W.; Davis, B. D.; Martinez, J. M. S.; Plummer, J. T. Emergence of a Novel SARS-CoV-2 Variant in Southern California. JAMA 2021, 325, 1324–1326. DOI: 10.1001/jama.2021.1612.
- Public Health England. Variants: Distribution of Cases Data. GOV.UK. 18 February 2021. https://www.gov.uk/government/publications/covid-19-variants-genomically-confirmed-case-numbers/variants-distribution-of-cases-data (accessed Feb 18, 2021).
- Roberts, M. Another New Coronavirus Variant Seen in the UK. Health editor. BBC NEWS. February 2021. https://www.bbc.co.uk/news/health-56082573 (accessed Feb 16, 2021).
- B.1.525. Rambault Group, University of Edinburgh. PANGO Lineages. 15 February 2021. https://cov-lineages.org/global_report_B.1.525.html (accessed Feb 16, 2021).
- Annavajhala, M. K.; Mohri, H.; Zucker, J. E.; Sheng, Z.; Wang, P.; Gomez-Simmonds, A.; Ho, D. D.; Uhlemann, A. C. A Novel SARS-CoV-2 Variant of Concern, B.1.526, Identified in New York. medRxiv 2021. DOI: 10.1101/2021.02.23.21252259.
- West, A. P.; Barnes, C. O.; Yang, Z.; Bjorkman, P. J. SARS-CoV-2 Lineage B.1.526 Emerging in the New York Region Detected by Software Utility Created to Query the Spike Mutational Landscape. bioRxiv Preprint 2021. DOI: 10.1101/2021.02.14.431043. This version posted February 23.
- Nguyen, K. V.; Naviaux, R. K.; Nyhan, W. L. Lesch-Nyhan Disease: I. Construction of Expression Vectors for Hypoxanthine-Guanine Phosphoribosyltransferase (HGprt) Enzyme and Amyloid Precursor Protein (APP). Nucleosides Nucleotides Nucleic Acids 2020, 39, 905–922.
- Lurie, N.; Saville, M.; Hatchett, R.; Halton, J. Developing Covid-19 Vaccine at Pandemic Speed. N. Engl. J. Med. 2020, 1969–1973.
- Pfizer. Pfizer and BioNtech Announce Vaccine Candidate against COVID-19 Achieved Success in First Interim Analysis from Phase 3 Study. November 9, 2020. https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biotech-announe-vaccine-candidate-against.
- Moderna. Moderna’s COVID-19 Vaccine Candidate Meets Its Primary Efficacy Endpoint in the First Interim Analysis of the Phase 3 COVE Study. November 16, 2020. https://investors.modernatx.com/news-releases/news-release-details/modernas-covid-19-vaccine-candidate-meets-its-primary-efficacy.
- Polack, F. P.; Thomas, S. J.; Kitchin, N.; Absalon, J.; Gurtman, A.; Lockhart, S.; Perez, J. L.; Marc, G. P.; Moreira, E. D.; Zerbini, C.; et al. For the C4591001 Clinical Trial Group. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N. Engl. J. Med. 2020, 383, 2603–2615.
- Voysey, M.; Clemens, S. A. C.; Madhi, S. A.; Weckx, L. Y.; Folegatti, P. M.; Aley, P. K.; Angus, B.; Baillie, V. L.; Barnabas, S. L.; Bhorat, Q. E.; et al. Safety and Efficacy of the ChAdOx1 nCoV-19 Vaccine (AZD1222) against SARS-CoV-2: An Interim Analysis of Four Randomized Controlled Trials in Brazil, South Africa, and the UK. Lancet 2021, 397, 99–111.
- Logunov, D. Y.; Dolzhikova, I. V.; Shcheblyakov, D. V.; Tukhvatulin, A. I.; Zubkova, O. V.; Dzharullaeva, A. S.; Kovyrshina, A. V.; Lubenets, N. L.; Grousova, D. M.; Erokhova, A. S.; et al. Safety and Efficacy of an rAd26 and rAd5 Vector-Based Heterologous Prime-Boost COVID-19 Vaccine: An Interim Analysis of a Randomized Controlled Phase 3 Trial in Russia. Lancet 2021, 397, 671–681.
- Xia, S.; Duan, K.; Zhang, Y.; Zhao, D.; Zhang, H.; Xie, Z.; Li, X.; Peng, C.; Zhang, Y.; Zhang, Y.; et al. Effect of an Inactivated Vaccine against SARS-CoV-2 on Safety and Immunogenicity Outcomes. Interim Analysis of 2 Randomized Clinical Trials. JAMA 2020, 324, 951–960.
- World Health Organization. The COVID-19 Candidate Vaccine Landscape and Tracker. https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines.
- Novavax. Novavax COVID-19 Vaccine Demonstrates 89% Efficacy in UK Phase 3 Trial. January 28, 2021. https://ir.novavax.com/news-releases/news-release-details/novavax-covid-19-vaccine-demonstrates-893-efficacy-uk-phase-3.
- Johnson & Johnson. Johnson & Johnson COVID-19 Vaccine Authorized by U.S. FDA for Emergency Use-First Single-Shot Vaccine in Fight against Global Pandemic. February 27, 2021. https://www.jnj.com/johnson-johnson-announces-single-shot-janssencovid-19-vacccine-candidate-met-primary-endpoints-in-interrim-analysis-of-its-phase-3-ensemble-trial.
- Public Health England. Investigation of Novel SARS-CoV-2 Variants: Variant of Concern 202012/01. Technical briefing 5. 2021. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/957504/Variant_of_Concern_VOC_202012_01_Technical_Briefing_5_Englans.pdf.
- Harrington, D.; Kele, B.; Pereira, S.; Couto-Parada, X.; Riddell, A.; Forbes, S.; Dobbie, H.; Cutino-Moguel, T. Confirmed Reinfection with Severe Acute Respiratoty Syndrome Coronavirus 2 (SARS-CoV-2) Variant VOC-202012/01. Clin. Infect. Dis. 2021. [PMC free article] [PubMed] [CrossRef] [Google Scholar].
- Vasques Nonaka, C. K.; Miranda Franco, M.; Graf, T.; Almeida Mendes, A. V.; Santana de Aguiar, R.; Giovanetti, M.; de Freitas, S. Genomic Evidence of a SARS- CoV-2 Reinfection Case with E484K Spike Mutation in Brazil. Preprints [Preprint], 2021, January 26 [cited 2021 Feb 02]. DOI: 10.20944/preprints2021.0132.v1.
- Sabino, E. C.; Buss, L. F.; Carvalho, M. P.; Prete, C. A.; Crispim, M. A.; Fraiji, N. A.; Pereira, R. H. M.; Parag, K. V.; da Silva Peixoto, P.; Kraemer, M. U. G.; et al. Resurgence of COVID-19 in Manaus, Brazil, despite High Seroprevalence. Lancet 2021, 397, 452–455. DOI: 10.1016/S0140-6736(21)00183-5.
- Wang, P.; Lihong, L.; Iketani, S.; Luo, Y.; Guo, Y.; Wang, M.; Yu, J.; Zhang, B.; Kwong, P. D.; Graham, B. S.; et al. Increased Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7 to Antibody Neutralization. bioRxiv 428137 [Preprint], 2021, Jan 26 [cited 2021 Feb 02]. DOI: 10.1101/2021.01.25.428137.
- Jangra, S.; Ye, C.; Rathnasinghe, R.; Stadlbauer, D.; Krammer, F.; Simon, V.; Martinez-Sobrido, L.; Garcia-Sastre, A.; Schotsaert, M.; PVI Study Group. The E484K Mutation Inn the SARS-CoV-2 Spike Protein Reduces but Does Not Abolish Neutralizing Activity of Human Convalescent and Post-Vaccinated Sera. medRxiv 21250543 [Preprint], 2021, Jan 29 [cited 2021 Feb 02]. DOI: 10.1101/2021.01.26.21250543.
- Zhang, S. A Troubling New Pattern among the Coronavirus Variant. The Atlantic [Internet] 2021, Jan 18 [cited 2021 Feb 01]; Health. https://www.theatlantic.com/health/archive/2021/01/coronavirus-evolving-same-mutations-around-world/617721/.
- Naveca, F.; da Costa, C.; Nascimento, V.; Souza, V.; Corado, A.; Nascimento, F.; Costa, A.; Duarte, D.; Silva, G.; Mejia, M.; et al. SARS-CoV-2 Reinfection by the New Variant of Concern (VOC) P.1 in Amazonas, Brazil. Virological [Preprint], 2021, Jan 17 [cited 2021 Feb 04]. https://virological.org/t/sars-cov-2-reinfection-by-the.new-variant-of-concern-voc-p-1-in-amazonas-brazil/596.
- Wibmer, C. K.; Ayres, F.; Hermanus, T.; Madzivhandila, M.; Kgagudi, P.; Oosthuysen, B.; Lambson, B. E.; de Oliveira, T.; Vermeulen, M.; van der Berg, K.; et al. SARS-CoV-2 501Y.V2 Escape Neutralization by South Africa COVID-19 Donor Plasma. Nat. Med. 2021, 27, 622–625. DOI: 10.1038/s41591-021-01285-x.
- Madhi, S. A.; Baillie, V.; Cutland, C. L.; Voysey, M.; Koen, A. L.; Fairlie, L.; Padayachee, S. D.; Dheda, K.; Barnabas, S. l.; Bhorat, Q. E.; et al. Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant. N. Engl. J. Med. 2021. Published on March 16, at NEJM.org. DOI: 10.1056/NEJMoa2102214.
- Tumpey, T. M.; Garcia-Sastre, A.; Mikulasova, A.; Taubenberger, J. K.; Swayne, D. E.; Palese, P.; Basler, C. F. Existing Antivirals Are Effective against Influenza Viruses with Genes from the 1918 Pandemic Virus. Proc. Natl. Acad. Sci. USA. 2002, 99, 13849–13854.
- Tumpey, T. M.; Basler, C. F.; Aguilar, P. V.; Zeng, H.; Solorzano, A.; Swayne, D. E.; Cox, N. J.; Katz, J. M.; Taubenberger, J. K.; Palese, P.; Garcia-Sastre, A. Characterization of the Reconstructed 1918 Spanish Influenza Pandemic Virus. Science 2005, 310, 77–79.
- Trilla, A.; Trilla, G.; Daer, C. The 1918 “Spanish Flu” in Spain. Clin. Infect. Dis. 2008, 47, 668–673.
- Belshe, R. B. The Origins of Pandemic Influenza-Lessons from the 1918 Virus. N. Engl. J. Med. 2005, 353, 2209–2211.
- Horimoto, T.; Kawaoka, Y. Influenza: Lessons from Pat Pandemics, Warning from Current Incidents. Nat. Rev. Microbiol. 2005, 3, 591–600.
- Mendelson, M.; Nel, J.; Blumberg, L.; Madhi, S. A.; Dryden, M.; Stevens, W.; Venter, F. W. Long-COVID: An Evolving Problem with an Extensive Impact. SAMJ 2021, 111, 15433.
- Liang, X.; Zhu, Y.; Fang, Y. COVID-19 and Post-Traumatic Stress Disorder: A Vicious Circle Involving Immunosuppression. CNS Neurosci. Ther. 2020, 26, 876–878. https://doi.org/10.1111/cns.13431.
- Bridgland, V. M. E.; Moeck, E. K.; Green, D. M.; Swain, T. L.; Nayda, D. M.; Matson, L. A.; Hutchison, N. P.; Takarangi, M. K. T. Why the COVID-19 Pandemic Is a Traumatic Stressor. PLoS One 2021, 16, e0240146. DOI: 10.1371/journal.pone.0240146.
- de Almeida-Pititto, B.; Dualib, P. M.; Zajdenverg, L.; Dantas, J. R.; de Souza, F. D.; Rodacki, M.; Bertoluci, M. C.; on behalf of Brazilian Diabetes Society Study Group (SBD). Severity and Mortality of COVID-19 in Patients with Diabetes, Hypertension and Cardiovascular Disease: A Meta-Analysis. Diabetol. Metab. Symdr. 2020, 12, 75.
- Yanai, H. Metabolic Syndrome and COVID-19. Cardiol. Res. 2020, 11, 360–365.
- Nair, G. G.; Liu, J. S.; Russ, H. A.; Tran, S.; Saxton, M. S.; Chen, R.; Juang, C.; Li, M. L.; Nguyen, V. Q.; Giacometti, S.; et al. Recapitulating Endocrine Cell Clustering in Culture Promotes Maturation of Human Stem-Cell-Derived β Cells. Nat. Cell Biol. 2019, 21, 263–274.